'We expect to get the approval in the next few weeks,' says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL).
Dominic Xavier wonders if the PM will opt for the Indian-made COVID-19 vaccine for the sake of Atmanirbhar Bharat.
Dominic Xavier wonders when human beings can access the vaccine and terminate the mayhem caused by the coronavirus.
Russian COVID-19 vaccine Sputnik V vaccine will be available in nine more cities across India, including Bengaluru, Mumbai, Chennai, Visakhapatnam, Baddi, Kolhapur and Miryalaguda, informed the official twitter handle of Sputnik V.
The Indian pharma industry is estimated to grow at 9-11 per cent in 2021-22 and in the next few quarters, it will be driven by domestic and emerging markets, according to ratings agency ICRA. In a sample of 21 Indian pharmaceutical companies, ICRA said revenue growth was moderate at 6.4 per cent in the second quarter of FY22, down from 16 per cent in the first quarter of 2021-22. The normalisation of the base and pricing pressures in the US market were the major reasons for slowing growth momentum in Q2 FY22, even as growth under domestic and emerging markets remained healthy, ICRA said in a statement.
